Sucampo Pharmaceuticals (NASDAQ:SCMP)‘s stock had its “neutral” rating reissued by analysts at Mizuho in a research note issued on Wednesday. They currently have a $18.00 price target on the biopharmaceutical company’s stock, up from their prior price target of $14.00. Mizuho’s price objective points to a potential downside of 0.83% from the company’s current price.

Other research analysts have also issued reports about the company. Nomura started coverage on Sucampo Pharmaceuticals in a report on Monday, December 18th. They set a “buy” rating and a $43.00 target price on the stock. Maxim Group set a $23.00 target price on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, December 7th. B. Riley lifted their target price on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, December 6th. BidaskClub raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 5th. Finally, ValuEngine raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $21.58.

Sucampo Pharmaceuticals (NASDAQ SCMP) traded up $0.20 during trading hours on Wednesday, reaching $18.15. The company had a trading volume of 5,258,800 shares, compared to its average volume of 4,365,500. The firm has a market capitalization of $841.80, a price-to-earnings ratio of -5.42, a P/E/G ratio of 5.04 and a beta of 1.45. Sucampo Pharmaceuticals has a 1 year low of $9.30 and a 1 year high of $18.15. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. The firm had revenue of $61.27 million for the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. Sucampo Pharmaceuticals’s revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.30 earnings per share. equities analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

In related news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $16.50, for a total value of $825,000.00. Following the transaction, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.13% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System increased its stake in Sucampo Pharmaceuticals by 1.6% in the 2nd quarter. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 200 shares in the last quarter. Rhumbline Advisers increased its stake in Sucampo Pharmaceuticals by 0.9% in the 2nd quarter. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 423 shares in the last quarter. SG Americas Securities LLC grew its stake in Sucampo Pharmaceuticals by 5.6% during the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock valued at $126,000 after acquiring an additional 631 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Sucampo Pharmaceuticals by 4.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 790 shares in the last quarter. Finally, Thrivent Financial For Lutherans grew its stake in Sucampo Pharmaceuticals by 11.3% during the 2nd quarter. Thrivent Financial For Lutherans now owns 15,270 shares of the biopharmaceutical company’s stock valued at $160,000 after acquiring an additional 1,550 shares in the last quarter. 65.29% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/01/05/sucampo-pharmaceuticals-scmp-stock-rating-reaffirmed-by-mizuho.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.